Assignee
VIVIDION THERAPEUTICS INC
US·4 granted patents·14 pending applications·2 citations·filing 2018–2025
Top patents by PatentIndex Score
18 records- 0177US10781239B2In vivo engineered cereblon proteinVIVIDION THERAPEUTICS INC·Filed 2019·Granted Sep 22, 2020·1 cites·24 claims
- 0273US10869860B2Cereblon modulators and uses thereofVIVIDION THERAPEUTICS INC·Filed 2019·Granted Dec 22, 2020·1 cites·30 claims
- 0371US2025188040A1Pharmaceutical compositions comprising wrn helicase inhibitorsVIVIDION THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0469US12187685B2Pharmaceutical compositions comprising WRN helicase inhibitorsVIVIDION THERAPEUTICS INC·Filed 2023·Granted Jan 7, 2025·0 cites·23 claims
- 0569US2024067612A1Pharmaceutical compositions comprising wrn helicase inhibitorsVIVIDION THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0666US2022298213A1In vivo engineered cereblon proteinVIVIDION THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0761US2025011291A1Keap1 inhibitors and uses thereofVIVIDION THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0861US2025332156A1Pharmaceutical compositions comprising wrn helicase inhibitorsVIVIDION THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0961US2024226114A1Inhibitors and uses thereofVIVIDION THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1059US2024270705A1Compounds selective for jak1 and methods of useVIVIDION THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1158US2025026721A1Compounds and methods for modulating ras-pi3kVIVIDION THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1258US2025059161A1Compounds and methods for modulating stat3VIVIDION THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1358US2021002337A1In vivo engineered cereblon proteinVIVIDION THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1457US11771689B2Cereblon modulators and uses thereofVIVIDION THERAPEUTICS INC·Filed 2020·Granted Oct 3, 2023·0 cites·20 claims
- 1551US2024123078A1Compounds and methods for modulating immune-related proteinsVIVIDION THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1651US2025228866A1Crystalline form of (r)-1-(3-(3-(4-aminopyrimidin-2-yl)-5-chlorophenyl)morpholino)prop-2-en-1-oneVIVIDION THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1742US2023045737A1Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitmentVIVIDION THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1840US2020239530A1Compounds and methods of modulating protein degradationVIVIDION THERAPEUTICS INC·Filed 2018·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →